Loading the security overview…
Where the tokens are
| Quarter | Reported | EPS | EPS vs year ago | Revenue | Revenue vs year ago | Consensus EPS |
|---|---|---|---|---|---|---|
| Q2 FY26ended Jun 30, 2026 | Aug 4, 2026 | −$0.60 | −266.7% | $114.44M | +11.4% | −$0.19 |
| Q1 FY26ended Mar 31, 2026 | May 13, 2026 | −$2.16 | — | $102.25M | +17.4% | −$0.01 |
| Q4 FY25ended Dec 31, 2025 | — | −$0.63 | −415.0% | $120.99M | +26.5% | — |
| Q3 FY25ended Sep 30, 2025 | — | −$0.27 | — | $116.74M | +51.9% | — |
| Q2 FY25ended Jun 30, 2025 | — | $0.36 | — | $102.69M | +45.6% | — |
| Q1 FY25ended Mar 31, 2025 | — | −$0.23 | — | $87.12M | +39.6% | — |
| Q4 FY24ended Dec 31, 2024 | — | $0.20 | — | $95.64M | +66.6% | — |
| Q3 FY24ended Sep 30, 2024 | — | −$0.31 | — | $76.87M | +44.2% | — |
Growth compares each quarter with the same fiscal quarter a year earlier, and is left blank where that quarter is missing or its figure was zero or a loss. Consensus is the estimate published before each report. It usually refers to adjusted EPS, so it is shown beside the GAAP figure rather than subtracted from it: the difference would not be a beat or a miss.
Figures describe GeneDx shares, not any token. As of Aug 4, 2026, from Massive's standardised financials and the earnings calendar.
| Q2 FY24ended Jun 30, 2024 | — | −$1.10 | — | $70.51M | — | — |
| Q1 FY24ended Mar 31, 2024 | — | −$0.78 | — | $62.42M | — | — |
| Q4 FY23ended Dec 31, 2023 | — | −$0.99 | — | $57.42M | — | — |
| Q3 FY23ended Sep 30, 2023 | — | −$1.64 | — | $53.30M | — | — |